Skip to main content
main-content

Hematologic cancers

News and opinion

10-12-2018 | B-cell lymphoma | News

Long-term data further support axicabtagene ciloleucel use for refractory large B-cell lymphoma

The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7
ASH 2018; San Diego, California, USA; 1–4 December

07-12-2018 | Chronic lymphocytic leukemia | News

Ibrutinib plus obinutuzumab more effective than chemoimmunotherapy in CLL

Combining ibrutinib rather than chlorambucil with obinutuzumab significantly improves progression-free survival in previously untreated patients with chronic lymphocytic leukemia, phase III study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30788-5
ASH 2018; San Diego, California, USA; 1–4 December

05-12-2018 | Diffuse large B-cell lymphoma | News

Durable response to tisagenlecleucel shown in DLBCL

Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1804980
ASH 2018; San Diego, California, USA; 1–4 December

20-11-2018 | FDA | News

approvalsWatch

First-line peripheral T-cell lymphoma, AML drug use announced

Read more on these US FDA and UK NICE approvals here

19-10-2018 | Follicular lymphoma | News

Post-induction PET predicts outcome in follicular lymphoma

Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30618-1

17-10-2018 | Chronic lymphocytic leukemia | News

Duvelisib offers treatment alternative for patients with CLL/SLL

The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.

Source:

Blood 2018; doi:10.1182/blood-2018-05-850461

15-10-2018 | Acute lymphoblastic leukemia | Podcast | Audio

ALL and infection: Unpicking the connection

Professor Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role. (10.21)

05-10-2018 | Acute myeloid leukemia | News

Lomustine benefits older patients with favorable-, intermediate-risk AML

Adding lomustine to standard chemotherapy with idarubicin and cytarabine significantly improves survival in fit older patients with favorable- or intermediate-risk acute myeloid leukemia, phase III trial data show.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.7366
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.3539

05-10-2018 | FDA | News

approvalsWatch

NGS test approved for ALL, multiple myeloma residual disease

The US FDA announcement is reported here

28-09-2018 | Hematologic cancers | News

In other news: Hematologic cancer focus

This month we round-up four hematologic cancer trials, two looking at treatment options for older and younger patients with Hodgkin lymphoma, and two evaluating treatments for smoldering and relapsed or refractory multiple myeloma. Read on to find out more.

20-09-2018 | Hodgkin lymphoma | News

Hormonal biomarker shows ovarian toxicity of Hodgkin lymphoma treatment

Phase III trial data have highlighted the value of antimüllerian hormone as a biomarker of ovarian toxicity associated with different chemotherapy regimens for advanced Hodgkin lymphoma.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30500-X

20-09-2018 | FDA | News

approvalsWatch

Hairy cell leukemia cytotoxin therapy approved by FDA

More information on this announcement here

19-09-2018 | Myelodysplastic syndrome | News

Persistent mutations post-transplant predict MDS disease progression

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

Source:

N Engl J Med 2018; 379: 1028–1041

18-09-2018 | Supportive care | News

Allogeneic HSCT-treated patients often receive medically intense end-of-life care

A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.095

12-09-2018 | Pediatric leukemia | News

Levofloxacin reduces bacteremia during chemotherapy for childhood leukemia

Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.

Source:

JAMA 2018; 320:995–1004

11-09-2018 | Pediatric leukemia | News

Maternal hormonal contraceptive use linked to childhood non-lymphoid leukemia risk

The use of hormonal contraceptives just before and during pregnancy may significantly increase the risk for childhood non-lymphoid leukemia, Danish researchers report.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30479-0

07-09-2018 | Diffuse large B-cell lymphoma | News

Circulating tumor DNA predicts DLBCL outcomes

Pretreatment levels of circulating tumor DNA, as well as changes during therapy, are independently prognostic of outcomes in patients with diffuse large B-cell lymphoma and can add to established risk factors, findings indicate.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.5246

06-09-2018 | Follicular lymphoma | News

Lenalidomide plus rituximab comparable to follicular lymphoma standard of care

Treatment-naïve follicular lymphoma patients have similar outcomes regardless of whether they receive lenalidomide or chemotherapy in combination with rituximab, suggest phase III trial findings published in The New England Journal of Medicine.

Source:

N Engl J Med 2018; 379: 934–947

24-08-2018 | Chronic lymphocytic leukemia | News

Obinutuzumab plus venetoclax shows promise for chronic lymphocytic leukemia

Obinutuzumab and venetoclax, preceded by bendamustine debulking for high tumor loads, shows high response rates without unexpected or cumulative toxicities in patients with chronic lymphocytic leukemia, a phase II trial suggests.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30414-5
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30442-X

22-08-2018 | Non-Hodgkin lymphoma | News

Mogamulizumab improves cutaneous T-cell lymphoma outcomes

MAVORIC trial results support the use of the C-C chemokine receptor 4-targeted antibody mogamulizumab over the standard of care vorinostat in previously treated patients with mycosis fungoides or Sézary syndrome.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30379-6
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30449-2

image credits